Phase I/II trial of docetaxel and carboplatin in previously untreated patients with advanced non-small-cell lung cancer
| Autor: | Yasuhiro Yoshiike, Kaneo Suzuki, Akira Shoji, Takashi Ogura, Shigeki Odagiri, Kenichi Takahashi, Mariko Toda, Yuji Watanuki, Hiroshi Takahashi, Harumi Nishiyama |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment Neutropenia Gastroenterology chemistry.chemical_compound Internal medicine medicine Lung cancer neoplasms Chemotherapy Performance status business.industry Area under the curve Combination chemotherapy Hematology General Medicine medicine.disease Carboplatin Docetaxel chemistry Surgery business therapeutics medicine.drug |
| Zdroj: | International Journal of Clinical Oncology. 5:323-327 |
| ISSN: | 1341-9625 |
| Popis: | Background. This trial was conducted to determine the maximum tolerated dose (MTD) and principal toxicities of combinations of docetaxel and carboplatin administered every 3 weeks to patients with advanced non-small-cell lung cancer (NSCLC) previously untreated with chemotherapy, and to find suitable doses for phase II studies in Japanese subjects. Methods. Japanese patients with advanced NSCLC and performance status 0 to 2 according to the World Health Organization classification, but previously untreated with chemotherapy received docetaxel followed by carboplatin, each infused over a 1-h period. The carboplatin dose was based on the target area under the curve (AUC), using Calvert's formula. Dose levels studied were: docetaxel (mg/m2)/carboplatin AUC (mg/ml·min), 50/4, 60/4, and 60/5, repeated every 3 weeks. Granulocyte-colony stimulating factor (G-CSF) support was first used when dose-limiting toxicities (DLTs) were encountered. Results. Of 14 patients entered, 12 were assessable for toxicity and response. The MTD schedule was: docetaxel, 60 mg/m2, with carboplatin, AUC 5 mg/ml·min (DLTs in 3 of 3 patients). The recommended dosage was: docetaxel, 60 mg/m2, with carboplatin, AUC 4 mg/ml·min (DLTs in 2 of 6 patients). The main toxic effect was neutropenia, and any nonhematologic toxic effects were mild. No thrombocytopenia occurred. Six of the 12 patients (50%) showed responses; 4 of the 6 at the recommended doses. Conclusion. Docetaxel 60 mg/m2, given over a 1-h period, followed by carboplatin, AUC 4 mg/ml·min, given over a 1-h period, is recommended for phase II studies in Japan. This combined chemotherapy has mild toxicity, except for neutropenia, and is useful and easy to administer. We therefore believe that phase II and phase III studies of this therapy would be well justified. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink